JPWO2021029368A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021029368A5 JPWO2021029368A5 JP2021539277A JP2021539277A JPWO2021029368A5 JP WO2021029368 A5 JPWO2021029368 A5 JP WO2021029368A5 JP 2021539277 A JP2021539277 A JP 2021539277A JP 2021539277 A JP2021539277 A JP 2021539277A JP WO2021029368 A5 JPWO2021029368 A5 JP WO2021029368A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- cd1d
- immunostimulant
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 230000003308 immunostimulating effect Effects 0.000 claims description 15
- 239000002671 adjuvant Substances 0.000 claims description 14
- 229960001438 immunostimulant agent Drugs 0.000 claims description 11
- 239000003022 immunostimulating agent Substances 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 8
- 230000036039 immunity Effects 0.000 claims description 7
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 5
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 5
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 5
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 5
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 4
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 230000015788 innate immune response Effects 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 3
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 239000012190 activator Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024125691A JP7556630B1 (ja) | 2019-08-09 | 2024-08-01 | 人工アジュバントベクター細胞と免疫賦活化剤との併用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019147019 | 2019-08-09 | ||
| JP2019147019 | 2019-08-09 | ||
| JP2020086468 | 2020-05-18 | ||
| JP2020086468 | 2020-05-18 | ||
| PCT/JP2020/030402 WO2021029368A1 (ja) | 2019-08-09 | 2020-08-07 | 人工アジュバントベクター細胞と免疫賦活化剤との併用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024125691A Division JP7556630B1 (ja) | 2019-08-09 | 2024-08-01 | 人工アジュバントベクター細胞と免疫賦活化剤との併用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2021029368A1 JPWO2021029368A1 (https=) | 2021-02-18 |
| JPWO2021029368A5 true JPWO2021029368A5 (https=) | 2023-05-24 |
| JP7537766B2 JP7537766B2 (ja) | 2024-08-21 |
Family
ID=74569659
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539277A Active JP7537766B2 (ja) | 2019-08-09 | 2020-08-07 | 人工アジュバントベクター細胞と免疫賦活化剤との併用 |
| JP2024125691A Active JP7556630B1 (ja) | 2019-08-09 | 2024-08-01 | 人工アジュバントベクター細胞と免疫賦活化剤との併用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024125691A Active JP7556630B1 (ja) | 2019-08-09 | 2024-08-01 | 人工アジュバントベクター細胞と免疫賦活化剤との併用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220296705A1 (https=) |
| EP (1) | EP4011389A4 (https=) |
| JP (2) | JP7537766B2 (https=) |
| WO (1) | WO2021029368A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023078487A (ja) * | 2020-04-08 | 2023-06-07 | アステラス製薬株式会社 | がんの処置に用いるｐｐ６５含有人工アジュバントベクター細胞 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69519521T2 (de) | 1994-10-03 | 2001-06-28 | The Government Of The United States Of America, As Represented By The Secretary National Institute Of Health | Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus |
| JP2002112780A (ja) | 2000-10-03 | 2002-04-16 | Keio Gijuku | ヒト膀胱癌抗原 |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| JP2004147649A (ja) | 2002-10-11 | 2004-05-27 | Kumamoto Technology & Industry Foundation | 頭頚部癌の抗原 |
| JP2005139118A (ja) | 2003-11-07 | 2005-06-02 | Ortho Mcneil Pharmaceut Inc | 腫瘍の治療のための細胞治療方法 |
| JP5672647B2 (ja) * | 2006-02-22 | 2015-02-18 | 独立行政法人理化学研究所 | ＣＤ１ｄリガンドをパルスした、標的抗原及びＣＤ１ｄの共発現細胞による免疫療法 |
| US20130189302A1 (en) * | 2006-02-22 | 2013-07-25 | Riken | Immunotherapeutic method using artificial adjuvant vector cells that co-express cd1d and target antigen |
| KR101050829B1 (ko) * | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| JPWO2010061930A1 (ja) * | 2008-11-28 | 2012-04-26 | 独立行政法人理化学研究所 | ＣＤ１ｄ及び標的抗原の共発現アロ細胞を用いた免疫療法 |
| CA2809089C (en) | 2010-08-23 | 2018-12-18 | Board Of Regents, The University Of Texas System | Anti-ox40 antibodies and methods of using the same |
| EP2738253A4 (en) | 2011-07-29 | 2015-04-22 | Riken | CELL FOR USE IN IMMUNOTHERAPY WITH A MODIFIED NUCLEIC ACIDIC CONSTRUCTIVE FOR WILMS TUMORGEN PRODUCT OR FRAGMENT THEREOF, METHOD FOR PRODUCING THIS CELL AND NUCLEIC ACIDIC CONCRETE SAID |
| CA2845810C (en) | 2011-08-23 | 2017-03-28 | Board Of Regents, The University Of Texas System | Anti-ox40 antibodies and methods of using the same |
| WO2015069697A2 (en) | 2013-11-05 | 2015-05-14 | Nkt Therapeutics Inc. | Combination therapy |
| WO2015095423A2 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| WO2015112793A2 (en) * | 2014-01-27 | 2015-07-30 | St. Jude Children's Research Hospital, Inc. | Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof |
| KR20160146747A (ko) | 2014-03-31 | 2016-12-21 | 제넨테크, 인크. | 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법 |
| CA3280968A1 (en) * | 2015-04-23 | 2025-10-30 | Baylor College Of Medicine | Nkt-cell subset for in vivo persistence and therapeutic activity and propagation of same |
| AU2017335771A1 (en) | 2016-09-28 | 2019-02-28 | Musc Foundation For Research Development | Antibodies that bind interleukin-2 and uses thereof |
-
2020
- 2020-08-07 EP EP20852111.2A patent/EP4011389A4/en active Pending
- 2020-08-07 WO PCT/JP2020/030402 patent/WO2021029368A1/ja not_active Ceased
- 2020-08-07 US US17/633,353 patent/US20220296705A1/en active Pending
- 2020-08-07 JP JP2021539277A patent/JP7537766B2/ja active Active
-
2024
- 2024-08-01 JP JP2024125691A patent/JP7556630B1/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Navabi et al. | A clinical grade poly I: C-analogue (Ampligen®) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro | |
| Tovey et al. | Adjuvant activity of cytokines | |
| Floros et al. | Anticancer cytokines: biology and clinical effects of interferon-α2, interleukin (IL)-2, IL-15, IL-21, and IL-12 | |
| Zheng et al. | Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer | |
| Zhou et al. | Towards curative cancer immunotherapy: overcoming posttherapy tumor escape | |
| Alexandrescu et al. | Immunotherapy for melanoma: current status and perspectives | |
| Moschella et al. | Combination strategies for enhancing the efficacy of immunotherapy in cancer patients | |
| MX2022003884A (es) | Tratamientos contra el cancer de utero. | |
| CN110121335A (zh) | 药物递送组合物及其用途 | |
| WO2012006634A2 (en) | Prostate specific antigen (psa) peptide therapy | |
| CN105979961A (zh) | 用于治疗癌症和感染性疾病的方法和组合物 | |
| JP2019509715A5 (https=) | ||
| Ding et al. | Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects | |
| MX2021003067A (es) | Peptidos restringidos por b*44 para el uso en la inmunoterapia contra el cancer y metodos relacionados. | |
| MX2022005897A (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de pulmon, incluyendo el nsclc, el sclc y otros canceres. | |
| CR20200632A (es) | Péptidos restringidos por a*03 par el uso en la inmunoterapia contra el cáncer y métodos relacionados | |
| JPWO2021029368A5 (https=) | ||
| WO2005067460A3 (en) | Epha2 vaccines | |
| JP2014530627A5 (https=) | ||
| MX2020012255A (es) | Peptidos para el uso en la inmunoterapia contra el cancer. | |
| CN112703011A (zh) | 用于治疗癌症的方法和组合物 | |
| ES2923769T3 (es) | Procedimientos relacionados con composiciones de células dendríticas activadas para sujetos con cánceres avanzados | |
| US20060216269A1 (en) | Dendritic cell tumor injection (DCTI) therapy | |
| Hong et al. | A bacterial flagellin in combination with proinflammatory cytokines activates human monocyte-derived dendritic cells to generate cytotoxic T lymphocytes having increased homing signals to cancer | |
| CN102227224A (zh) | 用于主动免疫治疗的Th1接种疫苗引发 |